Yiqun Xia

Wenzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Romidepsin inhibits NRF2 and enhances the efficacy of adagrasib by inducing autophagic cell death in KRAS-mutant tumor cells.

Romidepsin inhibits NRF2 and enhances the efficacy of adagrasib by inducing autophagic cell death in KRAS-mutant tumor cells.

Journal: Bioorganic chemistry

Published: December 27, 2025

6-Methoxydihydrosanguinarine synergizes with cisplatin to enhance lung cancer cell death via ROS-mediated autophagy, ER stress, and JNK activation.

6-Methoxydihydrosanguinarine synergizes with cisplatin to enhance lung cancer cell death via ROS-mediated autophagy, ER stress, and JNK activation.

Journal: European journal of pharmacology

Published: August 25, 2025

Synergistic Anticancer Effects of Lenvatinib and Celastrol via ROS-Mediated ER Stress and JNK Signaling in Colon Cancer Cells.

Synergistic Anticancer Effects of Lenvatinib and Celastrol via ROS-Mediated ER Stress and JNK Signaling in Colon Cancer Cells.

Journal: Cancer research and treatment

Published: May 12, 2025

The glutamyl-prolyl-tRNA synthetase 1 inhibitor halofuginone exerts synergistic antitumor effects with bortezomib in colon cancer cells.

The glutamyl-prolyl-tRNA synthetase 1 inhibitor halofuginone exerts synergistic antitumor effects with bortezomib in colon cancer cells.

Journal: Toxicology and applied pharmacology

Published: April 22, 2025

Combination of B-AP15 and HSP90 inhibitor tanespimycin induces ROS-mediated cytotoxicity in human lung cancer cells.

Combination of B-AP15 and HSP90 inhibitor tanespimycin induces ROS-mediated cytotoxicity in human lung cancer cells.

Journal: BMC pharmacology & toxicology

Published: April 16, 2025

Panobinostat potentiates adagrasib-induced cell death by triggering autophagy in human non-small cell lung cancer.

Panobinostat potentiates adagrasib-induced cell death by triggering autophagy in human non-small cell lung cancer.

Journal: Cell death discovery

Published: March 10, 2025

Synergistic targeting of TrxR1 and ATM/AKT pathway in human colon cancer cells.

Synergistic targeting of TrxR1 and ATM/AKT pathway in human colon cancer cells.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: January 09, 2024

Combination of TrxR1 inhibitor and lenvatinib triggers ROS-dependent cell death in human lung cancer cells.

Combination of TrxR1 inhibitor and lenvatinib triggers ROS-dependent cell death in human lung cancer cells.

Journal: International journal of biological sciences

Published: May 14, 2023

Combination therapy with HSP90 inhibitors and piperlongumine promotes ROS-mediated ER stress in colon cancer cells.

Combination therapy with HSP90 inhibitors and piperlongumine promotes ROS-mediated ER stress in colon cancer cells.

Journal: Cell death discovery

Published: May 03, 2023

Compensatory combination of mTOR and TrxR inhibitors to cause oxidative stress and regression of tumors.

Compensatory combination of mTOR and TrxR inhibitors to cause oxidative stress and regression of tumors.

Journal: Theranostics

Published: August 17, 2020

Isodeoxyelephantopin Inactivates Thioredoxin Reductase 1 and Activates ROS-Mediated JNK Signaling Pathway to Exacerbate Cisplatin Effectiveness in Human Colon Cancer Cells.

Isodeoxyelephantopin Inactivates Thioredoxin Reductase 1 and Activates ROS-Mediated JNK Signaling Pathway to Exacerbate Cisplatin Effectiveness in Human Colon Cancer Cells.

Journal: Frontiers in cell and developmental biology

Published: July 06, 2020

Piperlongumine potentiates the antitumor efficacy of oxaliplatin through ROS induction in gastric cancer cells.

Piperlongumine potentiates the antitumor efficacy of oxaliplatin through ROS induction in gastric cancer cells.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: August 13, 2019

Showing 1-12 of 25

Last Updated: 09/26/2026